retatrutide triple hormone receptor agonist metabolic The data just dropped — and is rewriting what's possible in obesity medicine. 🧬 TRIUMPH-1 just released Phase 3 results, and the numbers are unlike anything we've seen from a medication The future of metabolic science

Results There were 504,151 individuals with 2965 kidney failure events during a median 2.35 (interquartile range 1.094.32) years of follow-up

Bottom line If your insurance denied coverage for Wegovy, Zepbound, or another GLP-1 medication, do not panic and do not give up

When the pH drops below their isoelectric point, their net charge becomes positive, allowing electrostatic interactions with negatively charged polysaccharides and making them highly appropriate for immobilization applications (285)

Article 12 mins Navigating AI-Related Risks: A Guide for Directors and Officers As AI evolves, directors and officers must maneuver through a complex landscape of regulatory and legal risks

Abstract Introduction: Lymphedema is a major public health issue for many women undergoing breast cancer treatment